The Cabinet Committee on Economic Affairs of India (CCEA) has decided to block Shanghai Fosun Pharmaceutical’s (HK: 02196) 8.5 billion yuan ($1.3 billion) takeover of the Indian drugmaker Gland Pharma, according to reports.
Bloomberg reported the news on Monday, and since then Fosun’s share price has dropped by 2% to HK$27.10 in Hong Kong.
It was more than a year ago when the agreement for Fosun to buy an 86% stake in the Indian injectables company backed by American investment company KKR.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze